REGENXBIO (NASDAQ:RGNX) Shares Down 6.1% - Here's Why

Key Points

• REGENXBIO shares fell 6.1% to about $10.59 despite reporting second-quarter adjusted EPS of $0.43 and revenue of $108.02 million, both well above analyst expectations.
• The company raised more than $200 million in July, extending its cash runway into late 2027, while key regulatory and clinical milestones—including RGX-202, RGX-121 and RGX-314 updates—are expected in 2026–2027.
• Investor sentiment remains mixed: analysts’ consensus is “Moderate Buy” with a $23.82 price target, but REGENXBIO remains loss-making, expects a full-year loss, and its valuation depends heavily on successful clinical and regulatory outcomes.

REGENXBIO Inc. (NASDAQ:RGNX - Get Free Report) was down 6.1% on Friday . The stock traded as low as $10.62 and last traded at $10.5940. 194,626 shares traded hands during mid-day trading, a decline of 87% from the average daily volume of 1,452,026 shares. The stock had previously closed at $11.28.

Key Stories Impacting REGENXBIO

Here are the key news stories impacting REGENXBIO this week:

• Positive Sentiment: Q2 results exceeded expectations. REGENXBIO reported adjusted earnings of $0.43 per share, well above analyst estimates ranging from $0.08 to $0.12, while revenue of $108.02 million surpassed the $97.63 million consensus estimate. The result compared with a $1.38-per-share loss in the year-ago quarter. REGENXBIO Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: Cash runway and regulatory milestones improved visibility. The company said more than $200 million of new capital raised in July extended its cash runway into the fourth quarter of 2027. The RGX-202 biologics license application for Duchenne muscular dystrophy remains on track to begin in the third quarter of 2026, with potential accelerated approval in the second half of 2027. REGENXBIO Q2 2026 Financial Results
• Positive Sentiment: Multiple clinical catalysts remain ahead. Topline data from the ATMOSPHERE and ASCENT studies of ABBV-RGX-314 for wet age-related macular degeneration are expected in the fourth quarter of 2026. REGENXBIO also reaffirmed a third-quarter 2026 resubmission plan for RGX-121 in Hunter syndrome following an FDA Type A meeting. REGENXBIO Cash Runway and RGX-202 Update
• Neutral Sentiment: Barclays maintained an “Equal Weight” rating but raised or reaffirmed a $12 price target, implying roughly 15% upside from the cited share price. The target suggests measured optimism rather than a strongly bullish view. Barclays Rating Update
• Negative Sentiment: REGENXBIO remains financially loss-making. Despite the quarterly profit, the company reported a deeply negative net margin, and analysts still expect a full-year loss. The stock therefore remains highly dependent on successful clinical results, regulatory filings and future commercialization.

Analyst Ratings Changes

A number of analysts have commented on the company. Morgan Stanley reissued an "overweight" rating on shares of REGENXBIO in a report on Friday. Robert W. Baird raised their target price on REGENXBIO from $27.00 to $32.00 and gave the company an "outperform" rating in a report on Monday, June 22nd. Zacks Research cut REGENXBIO from a "hold" rating to a "strong sell" rating in a research report on Tuesday, July 14th. Weiss Ratings reiterated a "sell (e+)" rating on shares of REGENXBIO in a report on Monday, June 8th. Finally, Bank of America lowered their price target on REGENXBIO from $25.00 to $14.00 and set a "buy" rating for the company in a research report on Friday, May 15th. Nine research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat, REGENXBIO currently has a consensus rating of "Moderate Buy" and an average price target of $23.82.

REGENXBIO Price Performance

The firm's fifty day moving average is $9.94 and its two-hundred day moving average is $9.42. The firm has a market capitalization of $535.61 million, a PE ratio of -1.86 and a beta of 0.94.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.08 by $0.35. REGENXBIO had a negative net margin of 330.23% and a negative return on equity of 232.50%. The firm had revenue of $108.02 million during the quarter, compared to analyst estimates of $97.63 million. As a group, equities research analysts predict that REGENXBIO Inc. will post -3.69 EPS for the current fiscal year.

Insider Activity

In related news, insider Steve Pakola sold 36,725 shares of the stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $12.86, for a total transaction of $472,283.50. Following the completion of the sale, the insider directly owned 213,009 shares of the company's stock, valued at approximately $2,739,295.74. This trade represents a 14.71% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders sold 73,803 shares of company stock valued at $886,937 over the last three months. Corporate insiders own 14.22% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Versant Capital Management Inc increased its position in shares of REGENXBIO by 60.4% during the 2nd quarter. Versant Capital Management Inc now owns 2,741 shares of the biotechnology company's stock valued at $33,000 after purchasing an additional 1,032 shares during the last quarter. Aquatic Capital Management LLC purchased a new position in shares of REGENXBIO in the 3rd quarter worth about $37,000. Captrust Financial Advisors purchased a new position in shares of REGENXBIO in the 2nd quarter worth about $85,000. Entropy Technologies LP bought a new position in REGENXBIO during the first quarter valued at about $87,000. Finally, Prudential Financial Inc. bought a new position in REGENXBIO during the second quarter valued at about $87,000. Hedge funds and other institutional investors own 88.08% of the company's stock.

REGENXBIO Company Profile

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO's pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source